Major research centers and global biotech companies are racing to develop what has become known as "Digital Genetic Twins," a revolutionary concept that combines DNA sequencing techniques with superior artificial intelligence algorithms, to open the door to building a complete and complex digital simulation of the human body that allows doctors to predict diseases years before their first clinical symptoms appear.

According to specialized sources, this emerging technology relies on building a virtual replica of the patient, which simulates his accurate biological and genomic characteristics by continuously feeding them with medical records and daily biodata derived from wearable devices.

The technical sources indicated that this software twin allows dozens of therapeutic scenarios and drugs to be tested virtually on the digital version to see their response and possible side effects, before formulating or prescribing any real treatment for the patient in reality.

From heavy industry to genetic engineering

For many years, the concept of a "digital twin" has been the preserve of heavy industry and the aerospace sectors, with giants such as Boeing or General Electric building virtual versions of jet engines to predict and maintain breakdowns in advance, but transferring this model to the human body represents an unprecedented quantum leap that ends the philosophy of traditional medicine based on "reactive" and waiting for disease to emerge, and shifting toward proactive, data-driven preventive medicine.

On a practical level, pioneering projects have emerged such as Precision AI's Doctor Twin AI system, which converts genomic data into a medically searchable twin to predict the risk of more than 22,000 diseases.

In collaboration with NVIDIA and prestigious universities such as Stanford and Berkeley, the Ark Institute has developed the Evo 2 model, a genomic artificial intelligence system that has been trained on 9 trillion base pairs of DNA and has proven unparalleled efficiency in identifying mutations that cause breast cancer with high accuracy, according to the scientific journal Nature.

NLearn AI, in collaboration with Johnson & Johnson, has successfully created virtual patients for use as digital control kits, reducing the size of real volunteer samples in Phase III trials for Alzheimer's disease by nearly a third, amid cautious regulatory openness by the European Medicines Agency.

The phenomenon of "anxious healthy people"

Despite the glittering medical promises, this digital boom raises very complex ethical and economic concerns and concerns, perhaps the most prominent of which are:

Psychological Burden and the Nucebo Effect: Behavioral experts warn that individuals may become "anxious healthy people", as knowing that a person is statistically likely to develop a terminal illness in the future without the existence of current actual treatment may destroy their quality of life and put them in a cycle of ongoing morbid anxiety.

Genetic discrimination in the labor market and insurance: There are real concerns about the exploitation of these predictive software files by health insurance companies or employers, as insurance companies may charge disable premiums or refuse coverage based on an algorithmic expectation that a person will develop a disease at the age of 50, or human resources departments may refuse to hire talent based on a simulation that predicts chronic fatigue or depression after years of work.

In light of the current legislative vacuum, Harvard researchers argue that current laws such as the US Prohibition of Discrimination in Genetic Information Act (GINA) or the European General Data Protection Regulation (GDPR) still fall short of providing comprehensive protection in the age of digital twins, necessitating the formulation of strict international frameworks that recognize genetic twins as exclusive cryptographic property of their owner and criminalize access to them by any commercial or employers.